Resistance to tamoxifen-induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer.
about
Endocrinology and hormone therapy in breast cancer: new insight into estrogen receptor-alpha function and its implication for endocrine therapy resistance in breast cancerFulvestrant induces resistance by modulating GPER and CDK6 expression: implication of methyltransferases, deacetylases and the hSWI/SNF chromatin remodelling complexThe HER2-encoded miR-4728-3p regulates ESR1 through a non-canonical internal seed interactionCorrelation between estrogen receptor β expression and the curative effect of endocrine therapy in breast cancer patients.ERBB2 juxtamembrane domain (trastuzumab binding site) gene mutation is a rare event in invasive breast cancers overexpressing the ERBB2 gene.Fulvestrant-induced cell death and proteasomal degradation of estrogen receptor α protein in MCF-7 cells require the CSK c-Src tyrosine kinase.Loss of B-cell translocation gene 2 expression in estrogen receptor-positive breast cancer predicts tamoxifen resistance.Development of a peptide by phage display for SPECT imaging of resistance-susceptible breast cancerTherapeutic advances in BIG3-PHB2 inhibition targeting the crosstalk between estrogen and growth factors in breast cancerGrowth factor-induced resistance to tamoxifen is associated with a mutation of estrogen receptor alpha and its phosphorylation at serine 305.Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expressionThe development, application and limitations of breast cancer cell lines to study tamoxifen and aromatase inhibitor resistancePharmacology and anti-tumor activity of RWJ67657, a novel inhibitor of p38 mitogen activated protein kinaseNodes-and-connections RNAi knockdown screening: identification of a signaling molecule network involved in fulvestrant action and breast cancer prognosis.ERβ overexpression results in endocrine therapy resistance and poor prognosis in postmenopausal ERα-positive breast cancer patients.Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance.The role of Herceptin in early breast cancerSensitization of estrogen receptor-positive breast cancer cell lines to 4-hydroxytamoxifen by isothiocyanates present in cruciferous plants.Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance.Oncogenic MUC1-C promotes tamoxifen resistance in human breast cancer.Genistein sensitizes inhibitory effect of tamoxifen on the growth of estrogen receptor-positive and HER2-overexpressing human breast cancer cells.AKT-aro and HER2-aro, models for de novo resistance to aromatase inhibitors; molecular characterization and inhibitor response studiesBidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications.Significance of ERβ expression in different molecular subtypes of breast cancer.Epigenetic modulation: a novel therapeutic target for overcoming hormonal therapy resistance.Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications.Endocrine therapy resistance in breast cancer: current status, possible mechanisms and overcoming strategies.GDNF induces RET-SRC-HER2-dependent growth in trastuzumab-sensitive but SRC-independent growth in resistant breast tumor cells.Leptin increases HER2 protein levels through a STAT3-mediated up-regulation of Hsp90 in breast cancer cellsMinireview: The Link Between ERα Corepressors and Histone Deacetylases in Tamoxifen Resistance in Breast Cancer.Mechanisms of FGFR3 actions in endocrine resistant breast cancer.G protein-coupled receptor 30 expression is up-regulated by EGF and TGF alpha in estrogen receptor alpha-positive cancer cells.Lower Beclin 1 downregulates HER2 expression to enhance tamoxifen sensitivity and predicts a favorable outcome for ER positive breast cancerNew insights into the metastatic behavior after breast cancer surgery, according to well-established clinicopathological variables and molecular subtypes.Non-palpable breast carcinomas: correlation of mammographically detected malignant-appearing microcalcifications and molecular prognostic factors.
P2860
Q24813627-36440646-46E3-48A7-9576-43328AE4B025Q28301066-271BBFA4-B17C-4FE6-88C9-0A0E7ED19291Q33609935-E526C126-9C94-457E-8829-BBA6EC536043Q33706176-4C9E3B41-F7C9-4744-95C2-56E3DE643921Q33875241-DA7E24A7-A149-4A7C-8728-562EA3569BC7Q34674316-A9BBDDE8-7EA5-41F0-A2AE-3699A249AE7EQ35051765-E7424E3A-2BAD-4257-96E1-CD81DF01FDB6Q35229181-0C1721D8-0567-44BD-8578-92133E4517DCQ35674177-78CD50DC-6404-4259-9D34-FF9F9D419FBDQ35786706-33AD3C97-C40D-42D8-B921-66C5B01CFA38Q35786712-F47E6121-6EA1-4ED6-A98F-0B58A6BA4BADQ36013029-48129EA4-14E9-42E7-AB87-E9A7DD52FA1CQ36135818-0D38D13C-5B68-47F2-9A89-E0D606A6C85BQ36245954-994DA68D-D1BB-4CD3-BC85-86296BA41FCCQ36524735-A45111F4-C783-424E-A697-F61B3BFFE664Q36589865-592CA9FA-27E7-4A11-BA88-3CC27A600C71Q36657407-A5212722-867C-4604-9B64-F492E96FA07BQ36762899-8A4A07B8-2F3B-46D1-B323-C102BADCBD1FQ36860992-18C24611-9E06-4921-933E-CC8DA0CFFB3BQ37038731-35DBFA47-092A-4AFE-B6F6-62D65971003AQ37195192-CC988884-0055-4C1B-827A-7E4D915E52A8Q37247518-4EBD2020-A108-4181-8096-8F709095A3ECQ37255088-DE47FF4B-908A-4CA0-B9EC-55C2B5343533Q37548570-695359DB-9161-4FEB-9427-B1BEB936471DQ37962586-32FC1C48-37D9-44A6-A987-8FF689E59407Q38125970-46153EC8-1B5C-4AC0-BD03-77C3C69E7475Q38573685-05FC6D64-D631-47DE-BD93-77534EA5CB28Q38719786-551BD05A-A792-4DE4-8DF6-D43D9A662F13Q39228672-7616001F-1681-4A4B-9256-C90AB44F50ADQ39434758-E1844FA0-3861-407B-BFDB-E86E9C441303Q39500283-7A4707DE-90E8-4EB4-AA2C-5E7F3273EFBFQ39800227-0127E854-30F6-4F5A-8791-B0D6CDC41782Q41592633-54095A51-D1A3-426D-BA6E-0106603F3167Q41702637-4C54C5CD-C7DE-48F3-88C2-8080A80DFF91Q44157521-10F8E193-4329-4F21-B56B-81AE89656083
P2860
Resistance to tamoxifen-induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Resistance to tamoxifen-induce ...... gen receptor in breast cancer.
@en
Resistance to tamoxifen-induce ...... gen receptor in breast cancer.
@nl
type
label
Resistance to tamoxifen-induce ...... gen receptor in breast cancer.
@en
Resistance to tamoxifen-induce ...... gen receptor in breast cancer.
@nl
prefLabel
Resistance to tamoxifen-induce ...... gen receptor in breast cancer.
@en
Resistance to tamoxifen-induce ...... gen receptor in breast cancer.
@nl
P2093
P2860
P356
P1476
Resistance to tamoxifen-induce ...... gen receptor in breast cancer.
@en
P2093
Chi-Hung Lin
Meei-Ling Sheu
Sang-Hue Yen
Shun-Chun Yang
Yih-Lin Chung
P2860
P304
P356
10.1002/IJC.1614
P577
2002-01-01T00:00:00Z